A Phase I Dose Escalation And Expanded Cohort Study Of Pf-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (Sclc), Castration Resistant Prostate Cancer (Crpc) And Follicular Lymphoma (fl)
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2018
At a glance
- Drugs PF-06821497 (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Prostate cancer; Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 14 Dec 2018 Planned End Date changed from 13 Feb 2023 to 15 May 2023.
- 14 Dec 2018 Planned primary completion date changed from 13 Feb 2023 to 15 May 2023.
- 12 Nov 2018 Planned End Date changed from 6 Oct 2023 to 13 Feb 2023.